Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

DOACs perform well in real-world AF study

ESC CONGRESS 2018

Key clinical point: Patients with atrial fibrillation had better survival on a direct oral anticoagulant.

Major finding: Direct oral anticoagulant–treated patients had a 19% relative reduction in all-cause death, compared with patients on a vitamin K antagonist.

Study details: The GARFIELD-AF registry, which included 26,742 patients with newly diagnosed atrial fibrillation.

Disclosures: GARFIELD-AF was funded in part by Bayer. Dr. Camm has been an adviser to Bayer, Boehringer Ingelheim, Daiichi Sankyo, and Pfizer/Bristol-Myers Squibb.

Read the article.

Citation:

ESC CONGRESS 2018